nilvadipine has been researched along with Angor Pectoris in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mechanism of the antianginal actions of nilvadipine was investigated in 11 patients with effort angina pectoris." | 7.67 | Effects of a new second generation calcium channel blocker, nilvadipine (FR34235), on exercise-induced hemodynamic changes in stable angina pectoris. ( Kamihara, S; Koide, M; Miyahara, T; Noda, S; Sotobata, I; Tsunekawa, A; Yokota, M, 1987) |
| "The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism." | 6.39 | Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995) |
| "The mechanism of the antianginal actions of nilvadipine was investigated in 11 patients with effort angina pectoris." | 3.67 | Effects of a new second generation calcium channel blocker, nilvadipine (FR34235), on exercise-induced hemodynamic changes in stable angina pectoris. ( Kamihara, S; Koide, M; Miyahara, T; Noda, S; Sotobata, I; Tsunekawa, A; Yokota, M, 1987) |
| "The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism." | 2.39 | Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brogden, RN | 1 |
| McTavish, D | 1 |
| Kamihara, S | 2 |
| Yokota, M | 2 |
| Iwase, M | 1 |
| Miyahara, T | 2 |
| Hayashi, H | 1 |
| Saito, H | 1 |
| Sugiyama, S | 1 |
| Ozawa, T | 1 |
| Koide, M | 1 |
| Tsunekawa, A | 1 |
| Noda, S | 1 |
| Sotobata, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nilvadipine and Angor Pectoris
| Article | Year |
|---|---|
Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
Topics: Aging; Angina Pectoris; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular | 1995 |
2 other studies available for nilvadipine and Angor Pectoris
| Article | Year |
|---|---|
Early detection of myocardial ischemia by myocardial free fatty acid extraction in patients with exercise-induced angina pectoris.
Topics: Angina Pectoris; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Coronary Disease; E | 1989 |
Effects of a new second generation calcium channel blocker, nilvadipine (FR34235), on exercise-induced hemodynamic changes in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Coronary Circulation; Electrocardiography; Exercise Test; Female; Hear | 1987 |